


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



IN RE APPLICATION OF:

J. Milton Harris, *et al.*

APPLICATION No.: 10/634,970

FILED: August 5, 2003

FOR: PURIFIED POLYMERS FOR MODIFICATION OF
SURFACES AND MOLECULES

EXAMINER: David M. Naff

ART UNIT: 1657

CONF. No: 6943

Terminal Disclaimer

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Nektar Therapeutics AL, Corporation, Assignee of the entire right, title and interest in the above-identified patent application by virtue of an Assignment recorded in the U.S. Patent and Trademark Office at Reel 013467, Frame 0564, on March 4, 2003, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. § 154 to § 156 and § 173, as presently shortened by any terminal disclaimer, of co-pending application no. 10/119,546, filed on April 10, 2002.

The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the above-listed patents and/or patent applications are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. § 154 to § 156 and § 173 of the above-listed patents and/or applications, as presently shortened by any terminal disclaimer, in the event that said patent(s)/application(s) later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

07/10/2007 SSITHIB1 00000012 10634970

03 FC:1253

1020.00 DP

41714-8006.US00/LEGAL13374708.1

07/10/2007 SSITHIB1 00000012 10634970
02 FC:1814
130.00 DP

1. Authority of Undersigned


The undersigned is an attorney or agent of record.

2. Fee Payment

- ☒ A check for \$1940.00, which covers the Terminal Disclaimer fee under 37 C.F.R. § 1.20 (d) is enclosed.

Respectfully submitted,
Perkins Coie LLP

Date: July 5, 2007



Susan T. Evans
Registration No. 38,443
On behalf of Nektar Therapeutics

Correspondence Address:

Customer No. 21968